AARP's new research finds price growth for top Part D prescription drugs has exceeded inflation, making a case for allowing Medicare to negotiate prices.

Concurrently, a preprint from the industry-backed Vital Transformation found a 50% drop in company investments into small-molecule drug development.

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would not discuss Medicare's next round of negotiations because the list of selected drugs is not yet public.

Findings show the impact of drug companies’ relentless price increases, underscoring the importance of the changes included in the historic 2022 drug law

People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit, enrollees are responsible for 25 percent of their dr